| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2005;79:2109-2113
© 2005 The Society of Thoracic Surgeons
a Departments of Anesthesiology and Critical Care, Tenon University Hospital, Assistance Publique Hôpitaux de Paris, Paris
b Department of Thoracic and Vascular Surgery, Tenon University Hospital, Assistance Publique Hôpitaux de Paris, Paris
c Service et Laboratoire d’Anesthésie, UPRES Centre Hospitalier, Universitaire de Bicêtre, Université Paris-Sud, Faculté de Médecine du Kremlin-Bicêtre, Le Kremlin-Bicêtre, France
Accepted for publication July 12, 2004.
* Address reprint requests to Dr Marret, Département d’Anesthésie-Réanimation, Hopital Tenon, 4, Rue de la Chine, 75020 Paris, France (E-mail: emmanuel.marret{at}tnn.ap-hop-paris.fr).
PURPOSE: Paravertebral block in combination to intravenous analgesics could be an alternative to epidural analgesia for postoperative pain control after thoracotomy, but it has been scarcely evaluated so far. We thus assessed the efficacy of paravertebral block using a continuous infusion of ropivacaine in a multimodal analgesic approach.
DESCRIPTION: Forty patients were randomized to receive ketoprofen, paracetamol, and patient-controlled-analgesia (PCA) with intravenous morphine (control group) or the same treatment with a continuous 48-hour infusion of ropivacaine 0.5% (0.1 mL/kg–1/h–1) in a thoracic paravertebral catheter (thoracic paravertebral block [TPVB] group). Visual analog scale (VAS) at rest and when coughing, morphine consumption, and side effects were recorded during the first 48 hours after surgery. Venous blood was sampled at 24 and 48 hours for ropivacaine plasma concentration measurements.
EVALUATION: Mean VAS scores at rest and when coughing were significantly decreased in the TPBV group (p < 0.005). Despite a decrease in the morphine-titrated dose given in the postanesthesia care unit, cumulated morphine consumption was not significantly different between the two groups (51 ± 29 mg and 57 ± 24 mg in the TPVB and control groups, respectively). Side effects (nausea, vomiting, urinary retention) were less frequent in the TPBV group (30% vs 75%; p < 0.005). Plasma ropivacaine concentrations remained below the toxic threshold.
CONCLUSIONS: Continuous paravertebral ropivacaine 0.5% infusion improves pain control after thoracic surgery using a multimodal analgesic approach.
This article has been cited by other articles:
|
|
 |
|
  J. E. Chelly, A. Uskova, R. Merman, and D. Szczodry A multifactorial approach to the factors influencing determination of paravertebral depth: [Une approche multifactorielle des facteurs influencant l'evaluation de la profondeur paravertebrale] Can J Anesth, September 1, 2008; 55(9): 587 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Fibla, L. Molins, J. M. Mier, A. Sierra, and G. Vidal Comparative analysis of analgesic quality in the postoperative of thoracotomy: paravertebral block with bupivacaine 0.5% vs ropivacaine 0.2% Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 430 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Clavero, J. E. Cheyre, M. E. Solovera, and R. P. Aparicio Transient Diaphragmatic Paralysis by Continuous Para-Phrenic Infusion of Bupivacaine: A Novel Technique for the Management of Residual Spaces Ann. Thorac. Surg., March 1, 2007; 83(3): 1216 - 1218. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
